

Eremophilanolides from *Roldana lobata*

Jhon Maldonado^a, Amira Arciniegas^a, Ana-L. Pérez-Castorena^a, Mónica Arciniegas^a, José Luis Villaseñor^b, and Alfonso Romo de Vivar^a

^a Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, D.F., México

^b Instituto de Biología, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Coyoacán 04510, D.F., México

Reprint requests to Ana-L. Pérez-Castorena. Fax: (5255) 56-162217.

E-mail: alperzc@servidor.unam.mx

Z. Naturforsch. **2008**, *63b*, 331–334; received September 20, 2007

Three new eremophilanolides (**1–3**) and several known compounds were isolated from *Roldana lobata*. The structures of the new compounds were elucidated by spectroscopic methods. The cytotoxicity of the isolated compounds was tested against selected cancer cell lines.

Key words: *Roldana lobata*, Senecioneae, Eremophilanolides


Introduction

The genus *Roldana* (Asteraceae, Senecioneae, Tus-silaginiinae), spread from southern Arizona and New Mexico to Panamá, groups 48 species segregated from the genus *Senecio* [1, 2]. Some are used in Mexican folk medicine for a variety of ailments [3].



Previous investigations have shown that sesquiterpenes of the eremophilane or oplopane type, flavonoids, and plastoquinones are the main secondary metabolites reported in the eight members of this genus studied chemically so far [4–12]. This paper describes the first chemical study of *Roldana lobata* La Llave & Lex which resulted in the isolation and structure determination of three new eremophilanolides, 1 α -senecioyloxy-10 β -hydroxyeremophil-7(11)-en-8 α ,12-olide (**1**), 1 α -angeloyloxy-10 β -hydroxy-8 β -methoxyeremophil-7(11)-en-8 α ,12-olide (**2**), and 1 α -angeloyloxy-10 β -hydroxyeremophila-8,7(11)-dien-8,12-olide (**3**), in addition to the known eremophilanolides **4–6** [6, 7], and the flavonoids hyperin [13] and rutin [14]. Structures of the new compounds were determined by spectroscopic methods. The cytotoxicity of compounds **1–6** was tested against selected cancer cell lines.

Results and Discussion

Compound **1** showed a molecular formula C₂₀H₂₈O₅ by HRMS, and exhibited in the IR spectrum bands of hydroxyl, unsaturated γ -lactone and ester



- 1 R₁ = OSen, R₂ = OH, R₃ = H
- 2 R₁ = OAng, R₂ = OH, R₃ = OCH₃
- 4 R₁ = OAng, R₂ = OH, R₃ = H
- 5 R₁ = OAng, R₂ = H, R₃ = OH
- 6 R₁ = OAng, R₂ = OH, R₃ = OH



groups at 3519, 1742 and 1709 cm⁻¹, respectively. In the ¹H NMR spectrum (Table 1) the signal at δ = 5.73 (hept, J = 1.5 Hz) was attributed to the vinylic proton of the senecioyloxy group. COSY and HMBC experiments permitted to assign the signal at δ = 5.05 (dd, J = 11.5, 5.0 Hz) to H-1 and that at δ = 4.95 (br dd, J = 11.0, 8.0 Hz) to H-8. At higher field, in addition to the signals of the vinylic methyls of the senecioyloxy group (δ = 2.18, d, J = 1.5 Hz and 1.94, d, J = 1.5 Hz), appeared those of the methyl groups C-13 (δ = 1.82, t, J = 1.5 Hz), C-14 (δ = 1.07, s) and C-15 (δ = 0.85, d, J = 6.5 Hz), characteristic of an eremophilanolide skeleton. On the basis of the HMBC experiment, a hydroxyl group was localized at C-10 (δ = 76.9). The NOESY experiment showed cross peaks of CH₃-14 with H-1 and H-6 β , of H-8 with H-9 β and of H-9 α with H-4, suggesting the α orientation of both, the ester group and the γ -lactone function, since, on biogenetic grounds, the CH₃-14

Table 1. ^1H NMR (500 MHz) and ^{13}C NMR (125 MHz) data of compounds **1–3** (CDCl_3)^a.

No.	1		2^b		3	
	^1H	^{13}C	^1H	^{13}C	^1H	^{13}C
1	5.05 dd (11.5, 5.0)	74.9 d	5.18 dd (11.7, 5.4)	73.5 d	5.17 dd (11.0, 4.5)	75.2 d
2a	1.85 m	27.6 t	1.94 m	27.6 t	1.97 m	28.6 t
2b	1.45 m		1.37 m		1.49 m	
3	1.57 m	28.4 t	1.53 m	28.2 t	1.48 m	28.2 t
4	1.50 m	32.8 d	1.43 m	32.9 d	1.64 m	33.3 d
5		46.1 s		47.8 s		44.8 s
6 α	2.61 d (14.0)	32.2 t	2.55 d (13.8)	31.1 t	2.57 d (17.0)	29.7 t
6 β	2.53 dd (14.0, 1.5)		2.35 dq (13.8, 1.5)		2.73 dq (17.0, 2.0)	
7		160.8 s		155.6 s		146.6 s
8	4.95 br dd (11.0, 8.0)	78.3 d		105.2 s		151.4 s
9 β	2.54 dd (13.0, 8.0)	35.4 t	2.58 d (14.8)	37.8 t	5.82 s	105.3 d
9 α	1.71 dd (13.0, 11.0)		2.17 d (14.8)			
10		76.9 s		75.2 s		75.9 s
11		120.9 s		126.0 s		122.7 s
12		175.0 s		170.9 s		170.8 s
13	1.82 t (1.5)	8.3 q	1.91 d (1.5)	8.5 q	1.91 d (2.0)	8.4 q
14	1.07 s	14.8 q	1.10 s	14.9 q	1.13 s	14.5 q
15	0.85 d (6.5)	15.7 q	0.87 d (6.0)	15.8 q	0.82 d (6.5)	15.7 q
1'		167.7 s		167.4 s		168.2 s
2'	5.73 hept (1.5)	115.5 d		128.1 s		127.5 s
3'		151.1 s	6.06 qq (7.2, 1.5)	137.7 d	6.15 qq (7.0, 1.5)	139.4 d
4'	2.18 d (1.5)	20.5 q	1.98 dq (7.2, 1.5)	15.8 q	2.02 dq (7.0, 1.5)	15.9 q
5'	1.94 d (1.5)	27.5 q	1.91 quint (1.5)	20.7 q	1.94 quint (1.5)	20.6 q
OCH ₃			3.51 s	50.1 q		

^a Coupling constants (*J*) in Hz are in parentheses; ^b ^1H NMR (300 MHz) and ^{13}C NMR (75 MHz).

is β -oriented [15]. The homoallylic couplings of H-8 and H-6 β with CH₃-13, observed in the COSY experiment, are also in agreement with the β orientation of H-8 [16]. Finally, the *cis*-decaline configuration of **1** is in accordance with the chemical shift of the tertiary methyl group which resonates at lower field than the secondary methyl group [17].

Compound **2** also exhibited spectroscopic data consistent with an eremophilanolide skeleton. The molecular formula C₂₁H₃₀O₆(HRMS) showed one CH₂O unit more than in compound **1**. In the ^1H NMR spectrum (Table 1), the H-8 signal was absent, and those of a methoxy ($\delta = 3.51$) and of an angeloyloxy group ($\delta = 6.06$, qq, *J* = 7.2, 1.5 Hz; 1.98, dq, *J* = 7.2; 1.5 Hz; 1.91, quint, *J* = 1.5 Hz) were observed. COSY and HMBC NMR experiments allowed to place the methoxy group at C-8 ($\delta = 105.2$, s) and the angeloyloxy group at C-1 ($\delta = 73.5$, d). NOESY correlations between H-1 and CH₃-14 and between the methoxyl group and H-6 β , which also correlates with CH₃-14, permitted to propose for compound **2** the same stereochemistry as observed in **1**.

Eremophilanolide **3** presented a molecular formula C₂₀H₂₆O₅ by HRMS with an additional degree of unsaturation as compared to compound **1**. In the ^1H NMR

spectrum, the signal at $\delta = 6.15$ (qq, *J* = 7.0, 1.5 Hz) was assigned to the vinylic proton of an angeloyloxy group attached to C-1, and that at $\delta = 5.82$ to H-9, by 2D NMR experiments. The ester function should be α -equatorial, as in compounds **1** and **2**, since H-1 ($\delta = 5.17$, dd, *J* = 11.0, 4.5 Hz) showed an axial-axial coupling and correlated with CH₃-14 in the NOESY experiment. Finally, the hydroxyl group was placed β -orientated at C-10 ($\delta = 75.9$, s), as in compounds **1** and **2**.

The structures of the known compounds 1 α -angeloyloxy-10 β -hydroxyeremophil-7(11)-en-8 α ,12-olide (**4**) and 1 α -angeloyloxy-10 β H,8 β -hydroxyeremophil-7(11)-en-8,12-olide (**5**) were determined by comparison of their physical constants and spectroscopic features with those reported in the literature. 1 α -Angeloyloxy-10 β ,8 β -dihydroxyeremophil-7(11)-en-8,12-olide (**6**), hyperin, rutin, a sitosterol-stigmasterol mixture, sucrose and β -sitosterol glucoside were identified by comparison with authentic samples and by analysis of their spectroscopic data and physical constants.

Compounds **1–6** were tested against central nervous system (U-251), prostate (PC-3), leukemia (K562), colon (HCT-15), breast (MCF-7), and lung

(SKLU-1) human cancer cells following the protocols established by the National Cancer Institute [18]. Unfortunately, none of these compounds were active.

Experimental Section

General experimental procedures

Melting points were determined on a Fisher-Jones melting point apparatus and are uncorrected. Optical rotations were determined on a Perkin-Elmer 343 polarimeter. UV and IR spectra were recorded on a Shimadzu UV 160U and a Bruker Tensor 27 spectrometer, respectively. 1D and 2D NMR spectra were obtained on Eclipse JEOL 300 MHz, Bruker Avance 300 MHz or a Varian-Unity Inova 500 MHz spectrometers with tetramethylsilane (TMS) as internal standard. EIMS data were determined on a Bruker Daltonics Analysis 3.2 mass spectrometer. HRFABMS were performed at 10,000 resolution using electric field scans and polyethylene glycol ions (Fluka 200 and 300) as reference material. Column chromatography was carried out under vacuum on silica gel G 60 (Merck, Darmstadt, Germany). TLC was performed on silica gel 60 and preparative TLC on silica gel GF₂₅₄ (Merck), layer thickness 2.0 mm.

Plant material

Roldana lobata La Llave & Lex. was collected in Ozumba, Mexico State, Mexico, in October 2004. A voucher specimen (MEXU 394121) has been deposited at the Herbario del Instituto de Biología, Universidad Nacional Autónoma de México.

Extraction and isolation

Dried and ground roots (880 g) were extracted successively with hexane and methanol at r.t. The hexane extract (20 g) was separated by column chromatography eluted with a hexane-acetone gradient mixture system. Fractions eluted with hexane-acetone 19:1 and 9:1 (4.3 g) after column chromatography eluted with a hexane-acetone gradient system afforded compound **4** (860 mg) [6], fraction A and fraction B. Mother liquors of compound **4** (920 mg) were submitted to a new column chromatography eluted with hexane-acetone (19:1) to obtain **1** (10.5 mg) and **4** (127 mg). Compound **5** (40 mg) [6] was isolated from fraction A (350 mg) after column chromatography eluted with CH₂Cl₂-acetone 99:1, followed by preparative TLC eluted with hexane-acetone 19:1. Fraction B (405 mg) was worked up by successive column chromatographies in hexane-acetone 9:1 and CH₂Cl₂-acetone 99:1 to afford compound **6** [7] (68 mg) as colorless prisms from EtOAc-*i*Pr₂O, m.p. 158–160 °C, m.p. lit. 94–95 °C (a sample kindly supplied by the authors was a hydrate which lost water at 94–95 °C and melted at 156–157 °C). Fractions obtained from the first column

with hexane-acetone 8:2 (4 g) were purified by column chromatography eluted with hexane-acetone 9:1 to obtain **6** (760 mg).

The methanolic extract (71 g) was separated by column chromatography eluted with EtOAc-MeOH mixtures of increasing polarity. Fractions eluted with EtOAc (11.5 g) were fractionated by column chromatography eluted with hexane-EtOAc mixtures of increasing polarity. Fractions eluted with hexane-EtOAc 93:7 afforded 250 mg of **4**. Mother liquors of **4** were purified in a new column chromatography eluted with hexane-acetone 19:1 to afford 200 mg of **4** and fraction C. Fraction C (350 mg) was fractionated through a column chromatography eluted with CH₂Cl₂-hexane 8:2 and fractions 1–3 (80 mg) and 4–9 (120 mg) were further purified. Fractions 1–3 were submitted to preparative TLC eluted with hexane-acetone 9:1 to obtain compound **2** (25 mg). Fractions 4–9 were purified by preparative TLC eluted with C₆H₆-acetone 19:1 to produce compounds **2** (15 mg) and **3** (13 mg).

Dried and ground leaves (1 kg) were extracted with hexane and methanol, successively at r.t. The hexane extract (7.3 g), after purification by column chromatography eluted with hexane-acetone of increasing gradient of polarity afforded a sitosterol-stigmasterol mixture (430 mg). The methanolic extract (80 g) was fractionated by column chromatography eluting with EtOAc-MeOH mixtures of increasing polarity. Fractions eluted with EtOAc-MeOH 19:1 afforded sitosterol β -glucoside (50 mg). Fraction eluted with EtOAc-MeOH 9:1, after a new chromatography eluted with EtOAc-MeOH 19:1, produced hyperin (525 mg) [13]. Fractions eluted with EtOAc-MeOH 8:2 were purified on a sephadex column eluted with MeOH-H₂O 8:2 to obtain hyperin (300 mg), rutin (13 mg) [14], and sucrose (880 mg).

1\alpha-Seneciolyoxy-10 β -hydroxyeremophil-7(11)-en-8 α ,12-olide (1)

Colorless needles (EtOAc-*i*Pr₂O), m.p. 198–200 °C. – $[\alpha]_{\text{D}}^{25} = -36.3^{\circ}$ ($c = 0.19$, CHCl₃). – UV (MeOH): λ_{max} (lg ϵ_{max}) = 220 nm (4.2). – IR (CHCl₃): $\nu = 3519, 1742, 1709 \text{ cm}^{-1}$. – ¹H and ¹³C NMR spectral data: see Table 1. – MS (EI, 70 eV): m/z (%) = 348 (2) [M]⁺, 330 (10), 230 (30), 83 (100). – HRMS (FAB⁺): $m/z = 349.2017$ (calcd. 349.2015 for C₂₀H₂₉O₅, [M+H]⁺).

1\alpha-Angeloyloxy-10 β -hydroxy-8 β -methoxyeremophil-7(11)-en-8,12-olide (2)

Colorless needles (EtOAc-*i*Pr₂O), m.p. 98–100 °C. – $[\alpha]_{\text{D}}^{25} = +38.3^{\circ}$ ($c = 0.23$, MeOH). – UV (MeOH): λ_{max} (lg ϵ_{max}) = 218 nm (4.3). – IR (CHCl₃): $\nu = 3522, 1770, 1713 \text{ cm}^{-1}$. – ¹H and ¹³C NMR spectral data: see Table 1. – MS (EI, 70 eV): m/z (%) = 378 (2) [M]⁺, 346 (10), 228 (30), 278 (30), 83 (100). – HRMS (FAB⁺): $m/z = 379.2128$ (calcd. 379.2121 for C₂₁H₃₁O₆, [M+H]⁺).

1α-Angeloyloxy-10β-hydroxyeremophila-8,7(11)-dien-8,12-olide (3)

Colorless oil. – $[\alpha]_D^{25} = +42.9^\circ$ ($c = 0.27$, MeOH). – UV (MeOH): $\lambda_{\max}(\lg \epsilon_{\max}) = 220$ nm (4.1), 272 nm (4.1). – IR (CHCl₃): $\nu = 3486, 1776, 1715, 1677$ cm⁻¹. – ¹H NMR and ¹³C NMR spectral data: see Table 1. – MS (EI, 70 eV): m/z (%) = 346 (15) [M]⁺, 263 (100), 245 (70), 83 (95). – HRMS (FAB⁺): $m/z = 347.1857$ (calcd. 347.1858 for C₁₈H₁₉O₇, [M+H]⁺).

Acknowledgements

We thank Dr. Pedro Joseph-Nathan (Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional) for supplying a sample of compound **6**. We are also grateful to Héctor Ríos, Angeles Peña, Elizabeth Huerta, Nieves Zavala, Isabel Chávez, Rocío Patiño, Beatriz Quiróz, Luis Velasco, Javier Pérez, María Teresa Ramírez Apan, Eréndira García, and Gabriela Salcedo for technical assistance.

- [1] H. Robinson, R. D. Brettell, *Phytologia* **1974**, *27*, 402–429.
- [2] A. Fuston, *A revision of the genus Roldana*, Ph.D. Thesis, Kansas State University, Manhattan, K. S., **1999**.
- [3] A. Aguilar, J. Camacho, S. Chino, P. Jáquez, M. E. López, *Herbario Medicinal del Instituto Mexicano del Seguro Social*, Instituto Mexicano del Seguro Social, México, D. F., **1994**.
- [4] F. Bohlmann, C. Zdero, *Phytochemistry* **1978**, *17*, 565–566.
- [5] P. Joseph-Nathan, J. R. Villagómez, L. U. Román, J. D. Hernández, *Phytochemistry* **1990**, *29*, 977–979.
- [6] G. Delgado, P. E. García, R. Bye, E. Linares, *Phytochemistry* **1991**, *30*, 1716–1719.
- [7] E. Burgueño-Tapia, B. Hernández-Carlos, P. Joseph-Nathan, *J. Mol. Structure* **2006**, *825*, 115–123.
- [8] A. L. Pérez-Castorena, A. Arciniegas, M. T. Ramirez-Apan, J. L. Villaseñor, A. Romo de Vivar, *Planta Med.* **2002**, *68*, 645–647.
- [9] E. Burgeño-Tapia, P. Joseph-Nathan, *Magn. Reson. Chem.* **2003**, *41*, 386–390.
- [10] A. Arciniegas, A. L. Pérez-Castorena, J. L. Villaseñor, A. Romo de Vivar, *Biochem. System. Ecol.* **2004**, *32*, 615–618.
- [11] A. L. Pérez-Castorena, A. Arciniegas, M. L. Hernández, I. De la Rosa, J. L. Contreras, A. Romo de Vivar, *Z. Naturforsch.* **2005**, *60b*, 1088–1092.
- [12] A. Arciniegas, A. L. Pérez-Castorena, J. L. Villaseñor, A. Romo de Vivar, *J. Nat. Prod.* **2006**, *48*, 21–23.
- [13] K. R. Markham, B. Ternai, R. Stanley, H. Geiger, T. J. Mabry, *Tetrahedron* **1978**, *34*, 1389–1397.
- [14] E. Wenkert, H. Gottlieb, *Phytochemistry* **1977**, *16*, 1811–1816.
- [15] J. Richards, J. Hendrickson, *Biosynthesis of terpenes, steroids and acetogenins*; W. A. Benjamin, New York, **1964**, pp. 225–237.
- [16] J. Jizba, Z. Samek, L. Novotný, E. Najoenova, A. Boeva, *Coll. Czech. Chem. Commun.* **1978**, *43*, 1113–1124.
- [17] Y. Moriyama, T. Takahashi, *Bull. Chem. Soc. Jpn.* **1976**, *49*, 3196–3199.
- [18] A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paul, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, *J. Natl. Cancer Inst.* **1991**, *38*, 757–766.